Stock Update (NASDAQ:INSM): Insmed Incorporated Announces Upcoming Data Presentations at ERS 2015

Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases today reported two ARIKAYCE™ (liposomal amikacin for inhalation) posters will be presented at the European Respiratory Society (ERS) International Congress taking place in Amsterdam from September 26-30.

Summarized below are the poster titles and presentation times.

Poster Title: Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI)
Lead Author: K. Olivier
Poster Number: PA371
Date: Sunday, September 27, 2015
Session Time: 08:30-10:30 AM
Session Title: Bronchiectasis and NTM infections: clinical aspects and research outlook

Poster Title: A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC)
Lead Author: D. Griffith
Poster Number: PA3945
Date: Tuesday, September 29, 2015
Session Time: 12:50 PM-2:40 PM
Session Title: Novel strategies for the management of asthma, COPD and airway infections. (Original Source)

Shares of Insmed closed yesterday at $24.60. INSM has a 1-year high of $28.66 and a 1-year low of $12.17. The stock’s 50-day moving average is $25.50 and its 200-day moving average is $23.61.

Insmed Inc is a biopharmaceutical company engaged in developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. Its products candidates includes ARIKAYCE.